Melanoma Cell Lines: Metastatic melanoma cell lines from the primary lesions available

RGP-like melanoma cell lines
VGP-like melanoma cell lines
Cell lines of primary melanoma & metastasis from the same patients
Metastatic cell lines without available primary melanoma

Matastic melanoma cell lines without cells from the primary lesions available:

Cell line PLG #	Sex/ Age	AJCC pathology stage/ phase	Level/ thickness (mm)	Mitotic rate	Primary site	Specimen site	Primary refe -rence	Isolation date
WM9	M/n.a.	n.a.	n.a.	n.a.	n.a.	LN L axilla	(1,5,9)	08/03/78
WM46	F41	Stage 1 SSM RGP/VGP	IV/1.36	3.2	back	skin	(10)	02/02/79
WM164	M 21	Stage 3 NM VGP only	III/2.70	1.0	arm	LN	(3,5,11)	0/1/10/81
WM209	M 50	Stage 2 NM VGP only	V/5.0	0.0	face/ear	LN	n.a.	05/13/81
WM852	M 60	Stage 3 NM VGP only	III/1.20	3.0	abdomen	skin	(1,5)	05/02/83
WM1158	M 32	Stage 2 SSM RGP/VGP	III/2.75	n.a.	scalp/neck	LN	(12-14)	10/11/85
WM1852	M/n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	12/29/89
WM2067	M 41	Stage 2 SSM RGP/VGP	III/3.06	n.a.	back	LN axilla	n.a.	08/29/91
WM3214	F	n.a.	n.a.	n.a.	n.a.	Ax?	n.a.	09/30/94
WM3258	F 71	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	10/19/95
451Lu	M 21				WM164	lung (selection in mice)	(11,15)	n.a.
1205Lu	M 37				WM793	lung (selection in mice)	(16)	n.a.

^aDisease staging based on the manual for staging of cancer by the American Joint Committee on Cancer (AJCC). SSM: superficial spreading melanoma. NM: nodular melanoma. LMM: lentigo maligna melanoma. URGP: unclassified radial growth phases.
^b Anatomic levels of invasion is based on Clark's microstaging criteria.
^c L: left; R: right; LN: lymph node.
^d Disease staus as of August, 1997: NED: no evident disease; DOD: dead of disease; n.a.: information not available.
^e D: tissue dissociation.
^f D: DNA finger printing; H: HLA typing.
^g C: cells in culture available; F: frozen vials available.

References:
1. Herlyn , M., Thurin, J., Balaban, G., Bennicelli, J. L., Herlyn, D., Elder, D.,E., Clark, W.H., and Koprowski, H. Characteristics of cultured human malanocytes isolated from different stages of tumor progression. Cancer Res. 45: 5670, 1985.

2. Balaban, G., Herlyn, M., Guerry, D., IV, Bartolo, R., Koprowski, H., Clark, W.H., and Nowell, P.C. Cytogenics of human malignant melanoma and premalignant lesions. Cancer Genet. Cytogenet. 11: 428, 1984.

3. Satyamoorthy, K., DeJesus, E., Linnenbach, A.,J., Kraj, B. Kornreich, D.L., Rendel, S., Elder, D., and Herlyn, M. Melanoma cell lines from different stages of progression and their biological and molecular analyses. Melanoma Res. 7: S35, 1997.

4. Easty, D. J., Herlyn, M. and Bennett, D.C. Abnormal protein tyrosine kinase gene expression during melanoma progression and metastasis. Int. J. Cancer 60: 129. 1995.

5. Rodeck, U., Herlyn, M., Menssen, H.D., Furlanetto, R.W., Koprowski, H.: Metastatic but not primary melanoma cell lines grow in vitro independently of exogenous growth factors. Int J Cancer 40: 687, 1987.

6. Herlyn, M., Balaban, G., Bennicelli, J., Guerry, D.t., Halaban, R., Herlyn, D., Elder, D.E., Maul, G.G., Steplewski, Z., Nowell, P.C., et al.: Primary melanoma cells of the vertical growth phase: similarities to metastatic cells. J Natl Cancer Inst 74:283-289, 1985.

7. Kath, R., Rodeck, U., Parmiter, A., Jambrosic, J., Herlyn, M.: Growth factor independence in vitro of primary melanoma cells from advanced but not early or intermediate lesions. Cancer Therapy and Control 1:179-191, 1990.

8. Gyorfi, T. and Herlyn, M. Melanocyte and melanoma cell lines. In: R. J. Hay, J. G. Park and A. Gazdar (eds.), Atlas of Human Tumor Cell Lines. P. 413, Academic Press, Inc., 1994.

9. Zehngebot, L.M., Alexander, M.A., Guerry, D.t., Cines, D.B., Mitchell, K., Herlyn, M.: Functional consequence of variation in melanoma antigen expression. Cancer Immunol Immunother 16:30-34, 1983.

10. Herlyn, M., Clark, W.H., Jr., Mastrangelo, M.J., Guerry, D.P.t., Elder, D.E., LaRossa, D., Hamilton, R., Bondi, E., Tuthill, R., Steplewski, Z., Koprowski, H.: Specific immunoreactivity of hybridoma-secreted monoclonal anti-melanoma antibodies to cultured cells and freshly derived human cells. Cancer Res 40:3602-3609, 1980.

11. Herlyn, D., Iliopoulos, D., Jensen, P.J., Parmiter, A., Baird, J., Hotta, H., Adachi, K., Ross, A.H., Jambrosic, J., Koprowski, H., et al.: In vitro properties of human melanoma cells metastatic in nude mice. Cancer Res 50:2296-2302, 1990.

12. Becker, D., Beebe, S.J., Herlyn, M.: Differential expression of protein kinase C and cAMP-dependent protein kinase in normal human melanocytes and malignant melanomas. Oncogene 5:1133-1139, 1990.

13. Menrad, A., Speicher, D., Wacker, J., Herlyn, M.: Biochemical and functional characterization of aminopeptidase N expressed by human melanoma cells. Cancer Res 53:1450-1455, 1993.

14. Parmiter, A. H. and Nowell, P. C. The cytogenetics of human malignant melanoma and permalignant lesions. Cancer Treatment & Res. 43: 47, 1988.

15. Herlyn, D., Adachi, K., Koprowski, H. and Herlyn, M. Experimental model of human melanoma metastases. In: L. Nathanson (ed.) Melanoma Research: Genetics, Growth Factors, Metastases, and Antigens. p. 105. Boston, MA: Kluwer Academic Publishers, 1991.

16. Juhasz, I., Albelda, S.M., Elder, D.E., Murphy, G.F., Adachi, K., Herlyn, D., Valyi-Nagy, I.T., Herlyn, M.: Growth and invasion of human melanomas in human skin grafted to immunodeficient mice. Am J Pathol 143:528-537, 1993.